Saturday 17 October 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
17.06
0.73
−4.10%
Follow SRPT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 35.27 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.96 | 1.05 | 0.98 | 0.80 | |
P/FCF ratio |
25.27 | 21.11 | 0.00 | 0.00 | |
P/Operating CF |
9.61 | (11.27) | 16.42 | (132.44) | |
P/B ratio |
1.24 | 1.52 | 1.89 | 1.46 | |
Price to Tangible BV |
1.25 | 1.53 | 1.91 | 1.48 | |
EV/Sales |
1.04 | 1.17 | 0.97 | 0.91 | |
EV/EBITDA |
0.00 | 9,628.22 | 0.00 | 0.00 | |
EV/Operating CF |
18.43 | 14.61 | (10.39) | (9.02) | |
EV/FCF |
27.28 | 23.66 | (6.77) | (5.68) | |
Quick Ratio |
2.32 | 2.10 | 1.22 | 1.35 | |
Current Ratio |
4.42 | 4.63 | 2.32 | 2.95 | |
Net Debt/EBITDA |
2.59 | 0.50 | 0.27 | (2.14) | |
Debt/Assets |
26.58% | 26.37% | 24.75% | 29.63% | |
Debt/Equity |
0.55 | 0.56 | 0.73 | 0.78 | |
Asset Turnover |
0.57 | 0.66 | 0.60 | 0.68 | |
Operating CF/Net income |
(40.30) | (0.61) | (0.46) | 0.08 | |
Capex/Depreciation |
(0.06) | (0.31) | (0.77) | (1.66) | |
Research and Development Expense of Revenue |
22.74% | 21.07% | 73.45% | 54.81% | |
Selling, General and Administrative Expense of Revenue |
26.82% | 14.91% | 28.97% | 23.01% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.10% | 4.02% | 6.78% | 3.74% | |
Graham Net Nets |
0.30 | 0.28 | 0.15 | 0.28 | |
Graham Number |
0.00 | 14.11 | 0.00 | 0.00 | |
Earnings Yield |
(8.03%) | 2.84% | (33.15%) | (14.22%) | |
Free Cash Flow Yield |
3.96% | 4.74% | (14.64%) | (20.13%) | |
Revenue per Share |
3.81 | 6.96 | 4.42 | 3.98 | |
Operating CF per Share |
1.87 | (1.93) | 1.31 | (0.15) | |
Capex per Share |
(0.01) | (0.03) | (0.04) | (0.29) | |
Free Cash Flow per Share |
1.86 | (1.96) | 1.27 | (0.43) | |
Cash per Share |
7.48 | 6.22 | 9.39 | 8.49 | |
Shareholders Equity per Share |
14.49 | 14.34 | 11.39 | 13.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.49 | 14.34 | 11.39 | 13.17 | |
Free Cash Flow |
196.52 | (205.76) | 127.48 | (43.26) | |
Working Capital |
1,720.92 | 1,810.71 | 1,442.65 | 1,800.88 | |
Capital Expenditures |
(0.55) | (3.08) | (3.73) | (28.67) | |
Net Current Asset Value |
563.11 | 636.04 | 328.86 | 548.99 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
452.06 | 527.09 | 500.11 | 415.13 | |
Average Payables |
93.84 | 113.24 | 247.64 | 106.39 | |
Average Inventory |
949.15 | 971.27 | 832.35 | 821.55 | |
Average Assets |
3,434.16 | 3,322.16 | 3,656.44 | 3,546.69 | |
Average Common Equity |
1,442.59 | 1,323.91 | 1,334.18 | 1,270.60 |
Columns are period end dates